Collaborating for Cures
Leveraging Global Public-Private Partnerships to Accelerate Biopharmaceuticals Development

First Joint IMI & C-Path Forum on the Value of PPPs
Thursday 7 March 2013 – Brussels, Belgium
The Sheraton Hotel, Brussels Airport

9:00-10:00  Registration and refreshments

10:00-10:30  Welcome and introduction
Michel Goldman, Executive Director, IMI
Martha Brumfield, President and CEO, C-Path

10:30-12:30  Innovative solutions to shared challenges
Roundtable discussion – what challenges do PPPs face in areas such as knowledge management, sustainability, data sharing protection, intellectual property, ensuring industry involvement, addressing patients’ concerns, and evaluating the added value of PPPs? What solutions are in place and what challenges remain?
Chair: Orla Smith, Managing Editor, Science Translational Medicine
Panellists:
- Maria Freire, President, Foundation for the National Institutes of Health (FNIH)
- Tania Bubela, Associate Professor, School of Public Health, University of Alberta
- Alastair Benbow, Chief Executive, The Age of the Brain
- Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency
- ShaAvhree Buckman-Garner, Director, Office of Translational Sciences, CDER, FDA
- Richard Bergström, Director General, EFPIA

12:30-13:30  Lunch

13:30-15:30  IMI and C-Path collaboration on Alzheimer’s disease
Session Chairs: Elisabetta Vaudano, IMI Principal Scientific Manager
Gary Romano, Head, Neuroscience Biomarkers, Janssen Pharmaceutical Research and Development
Speakers: IMI’s PharmaCog project – Jill Richardson, GlaxoSmithKline
IMI’s EMIF project - Simon Lovestone, King’s College London
C-Path’s Coalition Against Major Diseases (CAMD) - Diane Stephenson, Executive Director
Panel discussion on the outcomes of the projects and their relevance in particular to regulators and patients

- Jill Richardson, Director, External Alliances and Development, R&D China
- Simon Lovestone, Director Biomedical Research Centre for Mental Health and Dementia, King’s College London
- Diane Stephenson, Executive Director, Coalition Against Major Diseases, Critical Path Institute
- Maria Isaac, Scientific Advisor, European Medicines Agency
- Russel G. Katz, FDA
- Maria Carrillo, Vice President, Medical & Scientific Relations, Alzheimer’s Association
- Jean Georges, Executive Director, Alzheimer Europe

15:30-16:00 Tea / coffee break

16:00-17:30 IMI and C-Path collaboration on tuberculosis
Session Chair: Elisabetta Vaudano, IMI Principal Scientific Manager
Speakers: IMI’s Predict-TB project – Justin Green, GSK & Gerry Davis, University of Liverpool
C-Path’s Critical Path to TB Drug Regimens (CPTR) project - Debra Hanna, Executive Director

Panel discussion on the outcomes of the projects and their relevance in particular to regulators and patients

- Justin Green, PreDiCT-TB Co-ordinator, GlaxoSmithKline
- Gerry Davies, Senior Lecturer in Infection pharmacology, University of Liverpool
- Debra Hanna, Executive Director, Critical Path to TB Drug Regimens Regulatory Science Consortium
- Bron Kisler, Vice President, Clinical Data Interchange Standards Consortium (CDISC)
- Edward Cox, Director, Office of Antimicrobial Products, FDA
- Joseph Toerner, Associate Director for Medical Affairs, FDA
- Marco Cavalier, Head of Anti-infectives and Vaccines, European Medicines Agency

17:30-17:50 Conclusions
Michel Goldman, Executive Director, IMI
Martha Brumfield, President and CEO, C-Path

17:50 End of the meeting